31 results about "Friedelin" patented technology

The present invention discloses the composition, extraction process and use of total triterpene sapogenin extracted from bamboo. The triterpene sapogenin is extracted from stem, branch, leaf, root, shoot, etc. of bamboo as one kind of gramineous plant via supercritical CO2 fluid extraction process. The test via vanillin-perchloric acid colorimetry method and GC-MS method shows that the extractive has total triterpene sapogenin content of 10-90 %, friedelin content of 5-35 % and lupenone content of 1-10 %. The extractive as one mixture of five-cycle triterpene compounds (EZR2002) has excellent physiological and pharmacological activity of resisting free radical, resisting oxidation, resisting tumor, lowering blood pressure, etc. and may be used in medicine and health care article for preventing and treating cardiac and cerebral vascular diseases and resisting tumor and may be also used in cosmetics.

The invention relates to a triterpene synthase of tripterygium wilfordii TwOSC3 protein and an encoding gene thereof. A recombinant expression vector with a Twosc3 gene is constructed by cloning cDNAof the Twosc3 gene onto a eukaryotic expression vector pYES2, and then the recombinant expression vector is shifted to yeast expression host bacteria, so as to acquire friedelin. A mutation research result shows that amino acid 482 encoded by the Twosc3 gene is a key site, and the yield of friedelin or amyrin can be increased or reduced; a gene gun mediated interference experiment shows that the interference of the Twosc3 gene has an obvious inhibiting effect on the synthesis of celastrol in tripterygium wilfordii; the TwOSC3 protein and the encoding gene thereof provided by the invention canbe used for biosynthesizing plant triterpenoids and cultivating high-quality tripterygium wilfordii.

The invention discloses a pouzolzia extract, a preparation method thereof, and an application thereof. According to the invention, for a first time, four compounds are separated and identified from subsiding swelling and pus removing effective parts of pouzolzia. A water extract prepared from pouzolzia and a chloroform or n-butyl alcohol extracted part thereof provide subsiding swelling and pus removing effects. The chloroform extracted part contains friedelin. The n-butyl alcohol extracted part contains kaempferol-7-O-alpha-L-pyran rhamnoside, quercetin-7-O-alpha-L-pyran rhamnoside, quercetin-3, and 7-O-alpha-L-2-pyran rhamnoside. The extract provided by the invention provides good subsiding swelling, pus removing, inflammation resisting, and pain relieving effects. The extract can be used for preparing subsiding swelling and pus removing medicines.

The invention relates to a triterpene synthase of tripterygium wilfordii TwOSC1 protein and an encoding gene thereof. A recombinant expression vector with a Twosc1 gene is constructed by cloning cDNAof the Twosc1 gene onto a eukaryotic expression vector pYES2, and then the recombinant expression vector is shifted to yeast expression host bacteria, so as to acquire some triterpenoids, such as friedelin and amyrin. A mutation research result shows that amino acids 486 and 502 encoded by the Twosc1 gene are key sites, and the yield of friedelin or amyrin can be increased or reduced; a gene gun mediated interference experiment shows that the interference of the Twosc1 gene has an obvious inhibiting effect on the synthesis of celastrol in the tripterygium wilfordii; through further experiments, a gene gun mediated overexpression experiment shows that the overexpression of the Twosc1 gene can increase the yield of the celastrol in tripterygium wilfordii suspension cells; the TwOSC1 proteinand the encoding gene thereof provided by the invention can be used for biosynthesizing plant triterpenoids and cultivating high-quality tripterygium wilfordii.

The invention belongs to the technical field of medicine, particularly relates to a medicinal composition for treating essential hypertension and application thereof. The medicinal composition is prepared from the following raw materials: Lycium barbarum polysaccharide component II, Lycium barbarum polysaccharide component III, friedelin-3beta-ol, Astragalus polysaccharide component A1 and Ajugol A. The medicinal composition provided by the invention has obvious therapeutic effect of inhibiting clinical symptoms of essential hypertension, has the advantages of stable quality control, no toxicity and is suitable for long-term administration.

The invention provides a composite medical film and a preparation method thereof. The composite medical film comprises the following components: low-density polyethylene, chitosan, friedelin, 3-hydroxyl-4-methoxybenzoic acid, kaempferol, quercetin, 2,7-dehydrate-beta-D- altroheptulo pyranoses, silicon dioxide, an antioxidant, a cross-linking agent and an antibacterial agent. The preparation method comprises the following steps: weighing all the components in parts by weight, feeding the components into a reaction kettle, heating in a nitrogen atmosphere, and continuously stirring to react, thereby obtaining a prefinished product; extruding the prefinished product in a double-screw extruder, thereby obtaining master batch; performing extrusion film blowing on the master batch in a plastic film blowing machine, thereby obtaining the composite medical film. The composite medical film provided by the invention is excellent in mechanical property, also good in biocompatibility, free of irritation to skin and just like normal saline, the tensile strength of the composite medical film is greater than 22MPa, and the steam permeation rate of the composite medical film is smaller than 3*10<-14>*(kg.m/(m<2>.s.Pa)).

The invention belongs to the field of drugs, and particularly relates to an anti-depression drug and application thereof. The active ingredients of the anti-depression drug at least comprise friedelin, preferably, the active ingredients of the anti-depression drug include the friedelin and pachymic acid A. When the friedelin and the pachymic acid A are used as a composition, the weight part ratioof the the friedelin to the pachymic acid A in the anti-depression drug is (2-4):1. Oral tablets are preferably selected as the form of the anti-depression drug. The accessories of the oral tablets comprise hydroxypropyl methylcellulose, lactose, povidone K30, magnesium stearate and talcum powder. The drug has an improvement effect on the behavioral features, caused by chronic unpredictable mild stress, of a rat depression model.

The invention discloses a pharmaceutical composition for treating diabetic retinopathy and a preparation method thereof. The pharmaceutical composition for treating diabetic retinopathy consists of the following components in parts by weight: coarse grain mixed powder, pseudolaric acid, p-chlorophenoxy isobutyric acid, syringin, phycocyanobilin, friedelin, stigmasterol, formononetin, L-alpha-aminoadipic acid, pancreatin, L-malic acid, vitamin and L-glutamic acid. The pharmaceutical composition disclosed by the invention realizes the effects of controlling blood glucose and treating retinopathy by improving glycometabolism, focusing on blood glucose reduction assisted by the medicinal components for nourishing yin and clearing heat and resolving stasis and by improving the human immunity to enhance the tolerance and resistance against lesion; and moreover, the pharmaceutical composition is simple in technology, realizes a good curative effect and can be promoted for application.

The invention discloses a preparation process of a bamboo composite board. The preparation method comprises the following steps: (1) preparing bamboo powder; (2) preparing a treating fluid; (3) performing primary vacuum treatment; (4) performing vacuum secondary treatment; and (5) performing hot pressing; According to the method, the bamboo powder is subjected to vacuum treatment by adopting a treatment liquid a and a treatment liquid b respectively, the obvious purification effect on the bamboo powder can be achieved, the content of polar compounds such as friedelin, oleic acid, gamma-sitosterol, hexadecanoic acid and 2,3-dihydrobenzofuran in the bamboo powder is reduced through combination of two times of treatment, and the internal organization structure of the bamboo powder is greatlyimproved.

The invention provides a pharmaceutical composition which comprises a pharmaceutical carrier and at least one compound selected from the group consisting of cobaltacene-octgomet, stigmastan-3,5-diene, galoxolide, benzyl salicylate, eucalyptol, and α-pinene. Also provided is a method of preparing a composition having antimicrobial activity comprising extracting a plant material in an organic solvent, contacting the extracted material to a chromatographic column, and eluting from the chromatographic column with a mobile polar phase to obtain a composition. The plant material is from Mammea Americana, Marchantaceae polymorpha, or Callistemon citrinus. Also provided is a method of inhibiting the growth of a mycobacterium, comprising administering a composition comprising a carrier and at least one compound selected from among cobaltacene-octgomet, stigmastan, 3,5-diene, friedelin, galoxolide, benzyl salicylate, eucalyptol, and α-pinene.

The invention provides a method for purifying friedelin, which is characterized by adopting supercritical carbon dioxide (CO2) extraction and macroporous resin purification friedelin. The method comprises the steps of extracting original medicinal material supercritical CO2, enabling extract to be soluble in sodium bicarbonate (NaHCO3) solution, filtering out insoluble substance, mixing and suspending on water, extracting by using trichloromethane, obtaining a trichloromethane layer for reducing pressure and recovering solvent, enabling the ethanol to be dissolved, adding defined amount macroporous resin to be evenly mixed, drying the solvent in a waving mode, conducting gradient elute on the water and ethanol solution in different concentration, collecting the eluent being rich in the friedelin, concentrating and drying backflow solution of ethyl acetate, stewing and crystallizing, filtering out crystallization and drying to obtain products. The method for purifying the friedelin is simple in step, good in selected separating effect, high in extraction efficiency and capable of being popularized and conducting large-scale production.

The invention belongs to the technical field of medicine, and particularly relates to a medicinal composition for preventing vascular dementia and an application thereof. The medicinal composition comprises the following raw materials: Lycium barbarum polysaccharide component II, Lycium barbarum polysaccharide component VI, Astragalus polysaccharides component A2, ajugol A and friedelin-3beta-ol. The medicinal composition provided by the invention has a remarkably curative effect on preventing vascular dementia, and has stable quality control and is suitable for long-term administration of patients.

The invention discloses a compound preparation for treating acute glomerulitis. The compound preparation for treating acute glomerulitis mainly comprises the following raw materials in parts by weight: 8-22 parts of raw radix astragalis, 2-6 parts of herba ephedra, 7-11 parts of evocarpine, 15-20 parts of friedelin, 12-18 parts of thiocolchicoside, 4-6 parts of 7-ethylcamptothecin, 4-8 parts of menthol, 26-28 parts of limonin, 7-12 parts of sissotrin and 2-4 parts of alisol A-24-acetate. In the medicine disclosed by the invention, the ingredients are strictly chosen according to the known mechanism of acute glomerulitis so as to achieve an aim of comprehensive rehabilitation; and the medicine has the characteristics of fast effect, stable action, convenience in carrying and taking and no toxic or side effect caused by long-term administration.

The invention relates to a recombinant yeast engineering bacterium capable of producing friedelin at high yield. The recombinant yeast engineering bacterium is used for over-expressing tHMG1, ERG1, ERG9 and ERG20; or tHMG1, ERG1, ERG9, and POS5; moreover, the BTS1, ROX1, YPL064w and YJL062w genes are knocked out, and after the tripterygium wilfordii friedelin encoding gene is introduced, friedelin can be efficiently expressed.

The invention discloses a Chinese and western medicine compound preparation for treating acute glomerulitis. The Chinese and western medicine compound preparation for treating the acute glomerulitis is prepared from the following main raw materials in parts by weight: 8-22 parts of astragalus membranaceus, 2-6 parts of poria cocos, 7-11 parts of evo-carpine, 15-20 parts of friedelin, 12-18 partsf of thiocolchicoside, 4-6 parts of 7-ethylcamptothecin, 4-8 parts of menthol, 26-28 parts of limonin, 7-12 parts of sissotrin and 2-4 parts of alisol A-24-acetate. The raw materials are strictly selected according to the known mechanism of the acute glomerulitis, so that the aim of comprehensive rehabilitation is achieved, and the Chinese and western medicine compound preparation has the characteristics of being high in effect taking speed, stable in action, convenient to carry and take and free of toxic or side effect after being taken for a long period of time.

The invention discloses a pharmaceutical composition for ultrasonic interventional therapy of pelvic abscess and a preparation method of the pharmaceutical composition. The pharmaceutical composition mainly consists of the following components in parts by weight: 3-8 parts of calculus bovis factitius, 2-5 parts of acetylsalicylic acid, 1-1.5 parts of solamargine, 0.01-0.03 parts of metronidazole, 0.2-1.2 parts of sanguinarine, 0.5-2 parts of chelerythrine, 0.8-3 parts of forsythol, 0.3-1.5 parts of hyperoside, 0.2-0.8 parts of isorhamnetin, 0.5-4 parts of houttuynin, 0.6-1 part of friedelin, 0.1-0.5 parts of kaempferol and 0.1-1 part of resveratrol. The pharmaceutical composition disclosed by the invention is a medicine which is prepared on the basis of inventor's researches for a long time in accordance with own clinical experiences; the pharmaceutical composition has functions of clearing heat and resisting bacteria, activating blood circulation to remove pus, suppressing inflammation and alleviating pains, and the pharmaceutical composition is capable of effectively resisting infection of various bacteria and boosting immunity; in combination with the ultrasonic interventional therapy, fine needle aspiration is conducted under the guidance of B ultrasound so as to directly reach a focus region, and the medicine is injected; therefore, the curative effect of the medicine is enhanced; and the pharmaceutical composition, on the pelvic abscess, is significant in curative effect, high in safety and free from obvious side effects.

The invention discloses a compound preparation for treating acute glomerulitis. The compound preparation for treating acute glomerulitis is prepared from the following main raw materials in parts by weight: 8-22 parts of harringtonine, 2-6 parts of didymin, 7-11 parts of fructus evodiae, 15-20 parts of friedelin, 12-18 parts of thiocolchicoside, 4-6 parts of 7-ethylcamptothecin, 4-8 parts of menthol, 26-28 parts of limonin, 7-12 parts of sissotrin and 2-4 parts of alisol A-24 acetate. The raw materials are strictly selected according to the known mechanism of the acute glomerulitis, so that the aim of comprehensive rehabilitation is achieved; and the compound preparation has the characteristics of being high in effect taking speed, stable in action, convenient to carry and take and free of toxic or side effect after being taken for a long period of time.